Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
STELAZINE is an injectable small-molecule antipsychotic approved in 1959 by GSK. The drug is indicated for psychiatric disorders and administered via injection. As a legacy antipsychotic, it represents an older generation of psychotropic therapy with established but narrow clinical use.
With LOE approaching and moderate competitive pressure (30%), this is a defensive, maintenance-focused asset with a lean team focused on retention rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
STELAZINE offers limited career growth opportunity given its mature, LOE-approaching status and zero linked job postings. Roles available focus on defensive brand management, maintaining market position, and managing transition to generic competition rather than launching or expanding the franchise.
Worked on STELAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.